Standout Papers

Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC... 2019 2026 2021 2023 299
  1. Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC (2019)
    Jhanelle E. Gray, Augusto Villegas et al. Journal of Thoracic Oncology

Immediate Impact

1 by Nobel laureates 68 standout
Sub-graph 1 of 21

Citing Papers

Ultrasound-Based Micro-/Nanosystems for Biomedical Applications
2024 Standout
Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study
2024 Standout
2 intermediate papers

Works of Augusto Villegas being referenced

Efficacy and safety evaluation based on time from completion of radiotherapy to randomization with durvalumab or placebo in pts from PACIFIC
2018
Efficacy, safety, and biomarker results of trastuzumab emtansine (T-DM1) in patients (pts) with previously treated HER2-overexpressing locally advanced or metastatic non-small cell lung cancer (mNSCLC).
2017

Author Peers

Author Last Decade Papers Cites
Augusto Villegas 594 611 78 148 27 824
Toshiro Yonei 494 530 90 84 28 831
David Vicente 447 443 71 56 29 702
Anqin Han 461 466 164 306 27 882
Anna-Larissa N. Niemeijer 439 768 74 225 15 942
G.P.M. ten Velde 604 443 99 69 31 901
Suchita Pakkala 509 670 98 41 32 948
Roshal R. Patel 326 572 120 119 43 889
Lawrence Einhorn 413 351 164 61 21 693
Puja Venkat 256 367 184 146 36 715
Vishram B. Rege 448 481 105 41 19 820

All Works

Loading papers...

Rankless by CCL
2026